gemcitabine has been researched along with melatonin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, H; Shen, J; Wu, A; Xu, C; Xu, L; Ye, J; Zhu, H | 1 |
| Bai, L; Chen, LZ; Chiao, PJ; Deng, W; Ju, HQ; Li, H; Lu, YX; Mo, HY; Sheng, H; Tian, T; Xu, RH; Zeng, JB | 1 |
| Bonior, J; Góralska, M; Jastrzębska, M; Jaworek, J; Leja-Szpak, A; Link-Lenczowski, P; Nawrot-Porąbka, K; Pierzchalski, P | 1 |
3 other study(ies) available for gemcitabine and melatonin
| Article | Year |
|---|---|
Melatonin is involved in the apoptosis and necrosis of pancreatic cancer cell line SW-1990 via modulating of Bcl-2/Bax balance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Melatonin; Mice; Mice, Inbred BALB C; Mice, Nude; Necrosis; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2 | 2013 |
Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Melatonin; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Proteins; NF-kappa B; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Melatonin and its metabolite N1-acetyl-N2-formyl-5-methoxykynuramine (afmk) enhance chemosensitivity to gemcitabine in pancreatic carcinoma cells (PANC-1).
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Kynuramine; Melatonin; Pancreatic Neoplasms | 2018 |